ETX E-therapeutics Plc

TIDMETX

RNS Number : 9219D

e-Therapeutics plc

02 July 2021

e-therapeutics plc

("e-therapeutics" or "the Company")

Achievement of further milestone in Galapagos collaboration

Oxford, UK, 2 July 2021 - e-therapeutics plc (AIM: ETX.L) announces that it has met a key milestone in its collaboration with Galapagos NV ("Galapagos"), a commercial stage company specialized in the discovery and development of small molecule medicines with novel modes of action, with a focus on inflammation, fibrosis and kidney disease. This milestone results in a payment from Galapagos. The objective of the collaboration between the Company and Galapagos, which was announced on 10 June 2020, is to identify new therapeutic approaches to modulate a specific mechanism involved in idiopathic pulmonary fibrosis (IPF) and other fibrotic indications.

Under the terms of the agreement, e-therapeutics is eligible to receive additional milestone payments through pre-clinical and clinical development as well as commercial milestones.

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented: "I am delighted with the progress of our collaboration with Galapagos following our recent update on 23 April 2021. We believe e-therapeutics' network biology approach will become an important component of small molecule drug discovery and we are implementing the same approach to our internal pipeline, using RNAi as the therapeutic modality of choice."

Market Abuse Regulation (MAR) Disclosure - Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Enquiries:

 
 e-therapeutics plc 
 Ali Mortazavi, CEO                             Tel: +44 (0)1993 883 
  Karl Keegan, CFO                                               125 
  Laura Roca-Alonso, CBO                     www.etherapeutics.co.uk 
 
 
 
   SP Angel Corporate Finance LLP                 Tel: +44(0)20 3470 
                                                                0470 
 Nominated Adviser and Broker 
 Matthew Johnson/Caroline Rowe (Corporate 
  Finance) 
 Vadim Alexandre/Rob Rees (Corporate 
  Broking) 
 
 

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small subsets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDKDBPPBKDKOK

(END) Dow Jones Newswires

July 02, 2021 02:00 ET (06:00 GMT)

E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024